<DOC>
	<DOCNO>NCT00477269</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , efficacy imatinib mesylate patient pulmonary arterial hypertension</brief_summary>
	<brief_title>Safety Efficacy Imatinib Mesylate Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Diagnosis PAH either primary ( idiopathic ) , familial secondary systemic sclerosis ( exclude mark pulmonary fibrosis ) accord World Conference Pulmonary Hypertension classification ( Venice , 2003 ) . Symptoms WHO class IIIV Use unspecific phosphodiesterase inhibitor ( example , pentoxyfillin , enoximon , milrinone pimobendan ) study Chronic inhale nitric oxide therapy start study completion Treatment catecholamine ( example , adrenalin , noradrenalin , dopamine ) , Preexisting lung disease , include parasitic disease affect lung , asthma , congenital abnormality lung , chest , diaphragm . Pulmonary artery valve stenosis ; pulmonary venous hypertension ; chronic thromboembolic pulmonary hypertension Acute heart failure chronic leave sided heart failure ; congenital acquire valvular myocardial disease Severe ( systemic ) arterial hypertension ( &gt; 200 mmHg ( systolic ) &gt; 120 mmHg ( diastolic ) ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Pulmonary Arterial Hypertension , tyrosine kinase inhibitor , STI571</keyword>
</DOC>